NeuroDP Therapeutics Inc. was founded at the intersection of molecular genetics and clinical neurology. Our journey began with a singular focus: to overcome the limitations of conventional Parkinson's treatments by leveraging the precision of AAV gene therapy. By engineering advanced viral vectors designed to deliver neuroprotective factors directly to the affected regions of the brain, we move beyond palliative care toward structural restoration. Our story is one of rigorous experimentation, scientific integrity, and an unwavering commitment to the patients who inspire our path forward.